CorMedix CEO Randy Milby noted the issuance of the Prosl patent is a significant addition to the company’s intellectual property portfolio in the EU.

"This patent will strengthen our ability to compete with other catheter lock solutions and help raise the standard of catheter care Europe," Milby added.

The company is the exclusive worldwide licensee of European Patent EP 1 814 562 B1, which was granted on 8 January 2014.

CorMedix’s first commercial product is Neutrolin, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients.